

Subject Index

BR: Book review

CR: Conference report

A

- Abciximab 269
- Absorption 181–185, 462–463, 466–468
- Absorption, distribution, metabolism and elimination (ADME) 408–409
- ABT-418 55
- Abzymes 239–247
- Acarbose 526
- ACE inhibitors 185, 186
 - in depression 536–537
 - pharmacokinetic parameters 182
- ACE-MS 537–538
- Acetals, cleavage 219
- Acetoacetate 148
- Acetylcholinesterase (AChE) inhibitors 305
 - in Alzheimer's dementia 55
- N-Acetyl- β -D-hexosaminidase 126–127
- N-Acetyl- α -D-mannosamine-1-phosphate analogues 83
- Acridines, 9-substituted 64
- Acronycine 172
- Active analog approach 432–433, 516–517
- Acylating agents, nonenzymatic 263
- Acyl-CoA:cholesterol acyltransferase inhibitors 40, 82
- Acyliminothiadiazoline derivatives 489
- N-Acyl-thiazoline-2-imines 459
- Adenomatous polyps, NSAIDs prevention 495
- Adenosine A₁ antagonist 533
- Adenosine A₃ antagonists 206–207
- Adenovirus protease 309
- Adhesins, microbial, inhibition 522–524
- Adhesion, inhibition 206, 303
 - competitive 522–526
 - see also* Cell adhesion molecules
- Adhesion molecules, *see* Cell adhesion molecules
- Adipocytes 112
- Adrenaline, binding to receptors 509
- α_2 -Adrenoceptors
 - agonist 534
 - antagonists 170
- β -Adrenoceptors, antagonists 183
- β_3 -Adrenoceptors
 - agonists 113–116
 - anti-obesity and antidiabetic activity 113–114
 - role in lipolysis 115
 - screening strategy 114–115
 - mutations in diabetes and obesity 114
- β_2 -Adrenoceptors 509
- Aequorin 497
- Affinity capillary electrophoresis-mass spectrometry (ACE-MS) 537–538
- AIDS
 - antisense oligonucleotide therapy 420
 - treatment 52
 - see also* HIV-1; HIV infection
- Airomir™ 407
- AKAP79 264
- Al-77-B 354
- Alcohol, dependence and withdrawal 380
- Aldehyde, asymmetric allylation 354
- Aldehyde addition reactions 147–150
- Aldol addition reactions 145–150
- α -Alkylated γ,δ -unsaturated amino acids 83
- 5-Alkylresorcinols 169
- Alliances, strategic, *see* Strategic alliances
- Allosterically potentiating ligands (APL) 55, 58
- Allosteric modulation, of nicotinic ACh receptor activity 55–57
- Allylation, of aldehydes 354
- Alzheimer's disease 305
 - corticotropin-releasing factor (CRF) 127
 - epipodophyllotoxins in 350
 - etiology and 'cholinergic hypothesis' 53–54
 - GABA_B receptors in 380
 - mutated presenilin genes 453
 - new animal model 49
 - new approach to drug therapy 53–59
 - allosteric modulation of nAChR 55–57
 - nicotinic noncompetitive agonists 55, 57–58
- Amantadine 321
- AmBisome 228
- American Association for the Advancement of Science (AAAS) 177–178
- Amgen, Consensus Interferon licensing 387
- Amines, secondary 220
- Amino acids
 - α -alkylated γ,δ -unsaturated 83
 - excitatory 456
 - utilization in combinatorial peptide libraries 450
- Aminoacyl tRNA synthase inhibitors 91
- γ -Aminobutyric acid, *see* GABA
- 2-Aminochromones 354
- Aminoglycoside antibiotics 226
- α -Amino-3-hydroxy-4-methylisooxazole-propionic acid (AMPA) 218
- 2'-Amino-nucleoside triphosphate 219
- 3'-Amino-nucleoside triphosphate 219
- 2-Aminopyrones 354
- 2-Aminothiazoles 459
 - library 402
- Amiodarone 269
- AMPA/kainate receptor antagonists 456
- AMPA receptor inhibitors 218, 456
- Amphotericin B 228
- β -Amyloid protein 453
 - learning impairment 49
- Amyloid P 303
- Anabaseine 55
- Analgesia 378–379
- Angiogenesis, inhibition/inhibitors 221, 492–493
- Angiotensin-converting enzyme inhibitors, *see* ACE inhibitors
- Angiotensin II, role in psychiatry 536–537
- Angiotensin II receptor antagonists 39–40, 489
 - balanced 218
- Angucyclinone antibiotics 172
- Animal behaviour, angiotensin II role 536
- Animal models, tumor immunology 194–195
- Animals, genetically engineered 92
- Anthraquinone ET_A-selective antagonists 61
- Anti-adhesion drugs/compounds 303, 522–526
- Anti- α Gal antibodies 525–526
- Antibacterial agents 499
- Antibiotic-resistant bacteria 315, 361
- Antibiotics
 - aminoglycoside 226
 - angucyclinone 172
 - antitumour 219
 - cephalosporins 183
 - genomics role 178
 - novel approach (symposium) 91
 - pyrrolo[2,1-c][1,4]benzodiazepine 219
 - see also* β -Lactam antibiotics

- Antibodies
 catalytic, *see* Catalytic
 antibodies
 natural
 blood group incompatibility 526
 in xenotransplantation 525–526
- Antibody engineering 243–244
- Anticancer drugs/agents 270–271, 401, 409–410
 antibiotics 219
 L-azatyrosine 401
 book review 46, 131
 protein kinase inhibitors 325–330
 taxol derivatives 497
 see also Cancer
- Antidepressant agents 261, 536–537
- Antifungal agents 228, 499
 analogues 493–494
 FR-900848 219
- Antigenic drift 317
- Anti-inflammatory activity, podophyllotoxin derivatives 346–348
- Anti-inflammatory agents, in asthma 205–206
- Antimicrobial agents 91
see also Antibiotics
- Antioxidant hypocholesterolemic agents 261
- Antiparasitic agents, combinatorial 355
- Antiplatelet therapy 269
- Antiproliferative retinoids 489–490
- Antipsychotic agents, atypical 217
- Anti-receptor antibodies 512
- Antisense drug development 417
- Antisense oligodeoxynucleotides (ODNs) 415–428
 book review 230
 clinical trials 418, 419–420
 delivery 425–426
 evaluation of efficacy 419–420
 future prospects 426–427
in vivo properties 423–424
 mechanism of action 415–417
 medicinal chemistry 424–425
 preclinical R&D 421–423
 target identification 417–418
- Antisense research, carbohydrate modifications (BR) 230
- Antitumor agents, *see* Anticancer agents
- Antitumour antibiotics 219
- Antiviral agents
 antisense oligonucleotides 418, 420
 for influenza virus 359–361
 phosphonobutoxypurine 533
 thionucleosides 123
- Anxiety, angiotensin II role 536
- AP-1 inhibitor 358
- L-AP4 [(S)-2-amino-4-phosphonobutyric acid] 105
- APC 366 203
- Apoptosis, osteoclasts 538
- Aqueous solubility 463–464
- AR 177–420
- Aromatase inhibitors 308, 449
 approval in France 413
- Array synthesis 252–253
- β -Arrestin 499
- Artificial intelligence algorithms 514
- 1-Aryl-3-alkyltriazenes 171
- 1-Aryl-3-(carbamoylmethyl)triazenes 171
- Aryl sulfonamides 62, 63
- 1-Aryl-2-(tosylamino)-1*H*-imidazoles 307
- AS 3738 347, 349
- AS 3739 349
- Aspirin, pharmacological mechanisms 49–50
- Assay(s)
 biochemical 358
 cell-free, antisense oligonucleotides 419
 enzyme 291–293
 fluorescence 313
 radioimmunoassay (RIA) 288–289
 radioligand binding 284–288
 receptor binding 289–290
 ultra-high-throughput 497
see also Scintillation proximity assay
- Assay development 277–286
 green fluorescent protein 497
- Assay optimization 277–286
- Assay technology 287
see also Scintillation proximity assay
- Asthma 199
- Asthma therapy 199–208
 award for 133
 novel approaches 199–208
 anti-inflammatory agents 205–206
 bronchodilators 201–205
 leukotriene antagonists 200–201
 leukotriene biosynthesis inhibitors 200–201
- Asymmetric allylation, aldehydes 354
- Asymmetric synthesis 145–150
 dihydroisocoumarin moiety of AL-77-B 354
 halenaquinone and halenaquinol 491
- ATPase, proton-pumping 309
- Aurin tricarboxylic acid 390, 392
- Aurora Biosciences Corporation 313–314
- Automation 458–460
 cost-benefit issues 8
 genomics application to lead generation 478
- International Symposium on Medicinal Chemistry 499
- ISLAR '95 symposium (CR) 7
- lead generation 46, 478
- problem-solving 481–488
- procedures and types 482–485
- software 484–485
- solid-phase synthesis 133, 458
- solution-phase synthesis 249, 459
- tasks appropriate for 481–482
- unitized vs component systems 483–484
- L-Azatyrosine 401
- 4-Azidobenzoyloxycarbamate prodrugs 400
- Azalactones 253
- B**
- Baclofen 371, 372, 374, 376, 378
- Bacteria
 adhesion inhibitors 522–524
 capsular polysaccharides 381–382
 toxins, antagonists 524
- Bacteriorhodopsins 504
- Balanoids 442–444
- Balanol 443
- BANA 393, 396
- Barry, D., personal 52
- Batimastat (British Biotech) 24, 25
- BAY-X-1005 201
- BAY-Y-1005 201
- BB 2516 24, 25
- BB 2576 493
- bcr/abl* gene, ribozyme inhibition 101
- BDC rat model 470–471
- Bead libraries, isotopic encoding 538
- Behaviour, angiotensin II role 536
- Benchmarking 272
- Benzimidazoles 68
- 1,4-Benzodiazepine-2,5-diones 142
- Benzodiazepine-2,5-diones 42–43
- Benzodiazepines 137
 combinatorial libraries 75, 137–138
 pharmacokinetic parameters 182
- Benzofuran carboxylic acids 64
- Benzol[*c*]phenanthridine alkaloids 491
- Benzol[*c*]thiophenes 220
- 2-Benzyl-4-aminopiperidines 490
- β -can structure 496
- Bimakalim 203
- Binding domains, cell adhesion molecules 295–296
- Bioavailability, oral, *see* Oral bioavailability

- Biochemical assays 358
Biogen, hepatitis B virus antigen patent dispute 35–38
Bioinformatics 272–274, 311, 475–476
Biological targets 126
discovery 11–15
Biomacromolecules, 3D database 315
Biomolecular screening 93, 267–268
Biotechnology patents, challengeability 35–38
Biphenyl library, 'universal' 355
Bisindolylmaleimide 440–441
Bisindolylmaleimide macrocycles 441–442
BL 1743 360, 361
Blood group incompatibility, blockade of antibodies 526
Blood–brain barrier 161–162
osmotic modification 163
Boronolide 491
BQ 123 68
BQ 788 68, 69
Brain injury, acute 456–458
Brasiliquinones A–C 490
BRCA1 gene product 223
Breast cancer
immunotherapy trials 196–198
Phase I study of batimastat 25
Breeding functions, in evolutionary algorithms 515
BRL 35135 113
BRL 37344 113, 115
BRL 49653 110, 111
BRL 55834 203
Bronchodilators 201–205
Butenolides 62–64
- C**
C1r serine protease inhibitors 305
Cachetic factor, tumor-derived 264
Cachexia 264
Caco-2 cells 467–468
Cadherins 302
Caelyx/Doxil 413
Calcineurine 42
Calcitonin-like receptors 504, 507, 510
Calcium, intracellular concentrations and probes for 314
Calcium channel(s), voltage-operated 457
Calcium channel antagonists (blocker) 225
neuronal 218
Calpain 457
Cambrex, Oxford Asymmetry agreement 274
CAMD (computer-aided molecular design) 311–312
Camppto (irinotecan) 413
Camptosar, FDA approval 413
Cancer
drugs in, *see* Anticancer drugs/agents
immunotherapy 190–198
trials 196–198
see also Vaccines, cancer
protein kinase C link 492
protein kinase inhibitor therapy 325–330
taxol derivatives 497
transcription factors and vaccines, *see* Vaccines, cancer
see also entries beginning
Tumor
Cannabinoid receptor, ligands 534
Caprylolactam 435
Capsular polysaccharides 381–382
as vaccines 382
Capsular polysaccharide-protein conjugate vaccines 381–387
design 393–385
immunogenicity 385–386
Captopril, in depression 537
CAPTURE trial 269
Carbacephems 354
Carbohydrate(s), modifications in antisense research (BR) 230
Carbohydrate-based contraceptives 333
Carbohydrate-based drugs 331, 332
Carbohydrate-based vaccines 190–198
Carboxylic acids 64
Carboxyphenylglycine [(S)-4-CPG] 105
Carcinogenicity studies, podophyllotoxin derivatives 348, 349
Cardiovascular disease
drug trials update 269
transcription factors and 156–157
Cardiovascular function, GABA_B receptors in 380
CARE (Cholesterol and Recurrent Events) trial 269
Carrier-mediated transport 181–185
Carvedilol 90
Catalysts, preparation 146–147
Catalytic antibodies 239–247
applications 240
commercialization 245–246
mechanisms of action 242–243
rate accelerations 241–242
selection methods 244–245
Catalytic systems 145–150
Cathepsin K 477
Cationic lipids 97
antisense oligodeoxynucleotides (ODNs) delivery 426
CD11b, antibody to 303
CD44 223
ligand 223
CDC25 phosphatase isoenzymes 42
cDNA
databases and libraries 477
strategic alliances and 475
cDNA-expressed enzymes 216
CDP 840 203
CDP 845 (Celltech) 25
Cell adhesion
compounds inhibiting 123, 206, 303, 353
proteins involved 302–303
Cell adhesion molecules 295–304
active sequences 295–304
applications and targets 303
binding domains 295–296
expression, inhibitors 123, 206, 353
ICAM-1 298–299
inhibitors 123, 206, 303
Cell culture technology, plant 271
Cell cycle control 404
Cell-free assays, antisense oligonucleotides 419
Cell-mediated lympholysis 347
Central nervous system
agents affecting 498–499
disorders 176–177
GABA_B receptors distribution 373–374
peptide delivery 161–168
see also Peptide(s)
Centre National de la Recherche Scientifique (CNRS), collaborative agreement 521
Cephalosporins, pharmacokinetic parameters 183
Ceranapril 536–537
Cerebral ischemia 107
Cerebral microcirculation 162
Cerebrus 176–177
c-fos gene, ribozyme action 100–101
CGP 12177 113, 115
CGP 35348 374, 375, 376
CGP 36742 374, 375, 377
CGP 55845 374, 375, 376
CGP 64128 420
Challenges, medicinal chemistry 529–532
Chaperone molecules 226
ChemDiverse method 74
Chemical Abstracts Service (CAS) 52
Chemical databases 131, 232–234
Chemical delivery systems 165–168
Chemical diversity, videos 275
Chemiluminescence 497
Chemokine inhibitors 205–206
Chemokine receptor family 509
Chemometric methods (BR) 412
Chemoselective glycosylation 336–339
Chimeric peptides 163–164
Chimeric receptors 511–512

- Chiral boron enolates 84
Chiral Europe '95 (CR) 7
 Chirality, titanium complexes 146
 Chiral technology, conference presentations 7
 Chiroscience, 3D database searching 236–237
 Chloride channels 223
 Chloroeremomycin 361
 Cholecystokinin-A (CCK_A) agonists 489
 Cholecystokinin-B (CCK_B) receptor antagonists 353
 Cholinergic hypothesis, of Alzheimer's dementia 53–54
 Cholinesterase (ChE) inhibitors in Alzheimer's dementia 54
see also Acetylcholinesterase (AChE) inhibitors
 ChromaXome Inc 48–49
 Ciba, letrozole approved in France 413
 Ciba-Geigy, Sandoz merger 176
 Ciglitazone 110, 111
 Ciprofloxacin resistance 315
 CIS Bio International 313
 CL 316243 113
 Clearance, drugs 181–185
 Clinical trials
 antisense oligodeoxynucleotides (ODNs) 418, 419–420
 cancer immunotherapy 196–198
 c-ras kinase in solid tumours 521
 matrix metalloproteinase inhibitors (MMPs) 24–25
 Phase II enzyme studies 213–214
Clostridium difficile 524
 Clustering methods 368
 Cocaine abuse 173
 Codeine 58
 Cognitive effects, GABA_B receptor antagonists 379
 Collagen 302
 Collagenase 16, 18, 21
 catalytic site 236
 inhibitors 22–23
 Colorectal cancer, NSAIDs prevention 495–496
 CombiChem 269
 Combinatorial biology 48
 Combinatorial chemistry 1, 129, 230, 311, 450
 2-aminothiazoles library 402
 antifungal analogues 493–494
 antiparasitic agents 355
 automation and (CR) 458–460
 COX-1 inhibitors 266
 data management 273
 decentralization of applications 459–460
 dihydropyridine synthesis 222
Exploiting Molecular Diversity (CR) 132–133
 genomics application 479–480
 International Symposium on Medicinal Chemistry (CR) 499
ISLAR '95 symposium (CR) 8–9
 lead optimization and genetic algorithm use 520
 medicinal chemistry and 530
 microautoradiographic screening 402
 molecular framework analysis 537
 small-molecule 134–144
 Society for Biomolecular Screening conference 85
 solution chemistry 308
 synthetic receptors 266
 video 275
 virtual libraries and 369–370
 Combinatorial library design 73–74
 oligosaccharide application 527
 Rauwolfia alkaloids 450
 solution-phase 248–254
 strategies 132
 see also Combinatorial chemistry; Compound libraries
 Combinatorial library technology
 oligosaccharides/glycoconjugates 27–34
 small-molecular libraries 42–43
 Complement, C1r serine protease inhibitor 305
 Complex carbohydrates 522–528
 see also Oligosaccharides
 Compound libraries 274
 evaluation of molecular diversity in 71–78
 screening, endothelin antagonists 61–70
 see also Combinatorial library
 Computational chemistry, video 275
 Computer-aided drug design (CADD) 71, 231–238
 Computer-aided molecular design (CAMD) 311–312
 Computer-based screening 363–370
 see also High-throughput screening (HTS)
 Computer modelling, molecular biology (BR) 500
 Computer software
 3D database searching 232
 for automation 484–485
 Conferences, partnering 79
 Conformational analysis/search 429–437
 Conformational flexibility, 3D database searching 232–234
 Conformational structure 185–188
 Conjugases 213, 214
 Contraceptive/contraception
 carbohydrate-based 333
 male 126–127, 309
 Contract research 176–177
 organizations (CROs) 255–260
 Convergent block synthesis 335–336
 Corallidictyal A/B 445
 Core competencies 258–260
 Corticotropin-releasing factor (CRF) 127
 Cosmetics industry 271
 Cosmids 475
 Covalent coupling, conjugate vaccines 383, 384–385
 COX-1 inhibitors 266
 COX-2 inhibitors 122–123
 CP 99994 203, 367
 CP 101606 457
 (S)-4-CPG (carboxyphenylglycine) 105
 CPH 82 347, 349
c-ras-1 gene 328–329
c-ras kinase, patent 521
 C-reactive protein 302
 CRO (contract research organization) 255–260
 Crosslinking, ligands and receptors 512
 Cruciform Project 88
 Cyanomethylation, diarylethenes 535
 Cyclin-dependent kinases (CDKs) 329
 Cyclin E-CDK2 kinase 223
 Cycloalkanes, stereoselective formation 309
 Cyclooxygenase inhibitors 122–123, 266
 Cyclosporin A (CsA) 187
 Cylexin 525
 Cystic fibrosis, new strategies 225–226
 Cystic fibrosis transmembrane conductance regulator (CFTR) 225–226
 Cytochrome P-450 211–212
 Cytokine inhibitors 205–206
 Cytoplasmic inhibitors, transcription factors 153, 159
- ## D
- d4T, novel prodrugs 306
 DANA (2-deoxy-2,3-dihydro-*N*-acetylneuraminic acid) 393, 394–395
 DAPH-1 327
 Database
 2D (two-dimensional) 363–364
 3D (three-dimensional) 363–364
 of biomacromolecules 315
 searching, *see* Database searching
 virtual libraries and 369–370
 computer-based screening 363–370

- Database searching
 2D database 231–232
 3D database 77, 231–238, 366–367
 Chiroscience experience 236–237
 strategies 234–236
 databases available 233
 genetic algorithms 517
 genomics 475
 lead generation 71–72
- Decoding strategies, library generation 249, 250
- Deconvolution strategies 27
- Dehydroepiandrosterone sulfatase inhibitors 308
- Dementia, Alzheimer's, *see* Alzheimer's dementia
- 4'-Demethylpodophyllotoxin 345
- 2-Deoxy-2'-fluoroguanosine (2-FDG) 390
- Deoxypodophyllotoxin 345
- β -2'-Deoxyribonucleosides 535
- 2'-Deoxy-2'-substituted-4'-thiocytidines 264
- Depression, ACE inhibitors 536–537
- Descriptors, lead generation and evaluation 73
- 'Design approach' 531
- Devised drug discovery 87, 88
- 3,5-DHPG (3,5-dihydroxyphenylglycine) 105
- Diabetes mellitus
 complications 221
 non-insulin-dependent (NIDDM) 109–116
see also Insulin resistance
- 3,5'-Diamino-3',5'-dideoxynucleosides 535
- 2,4-Diaminopyrrolo [1,2,3-*d*]pyrimidines 83
- Diarylethenes, cyanomethylation 535
- Dibenzodiazepine-10-acetic acid 68
- 8,9-Dicarboxydibenzol[2,3:5,6]-bicyclo[5,2,0]nonan-4-ones 68
- Differential display 13–15
- Dihydroisocoumarins 354
- Dihydropyridine anhydrides 66
- Dihydropyridines 143
 synthesis 222
- Dihydropyrimidines 143
- 3,4-Dihydroxy-*cis*-cinnamitrile 327
- Diisobutylaluminium hydride (DIBALH) 124
- Diketopiperazines 64, 138
- 3-Dimensional Pharmaceuticals Inc 46
- 1,3-Diol, library 140
- 1,3-Dioxolane ketals/acetal 219
- Dipeptidyl peptidase IV 398
- Diphenyl ethers 62
- DirectedDiversity™ 46
- 'Discovery approach' 531
- Disease
 human, transcription factors role 156–158
 management 119–120
- DIVALI (docking with evolutionary algorithms) 518
- DNA
 complimentary, *see* cDNA
 transcription factor binding 153, 159
- DNA markers, expressed sequence tags (ESTs) 12–13
- DNA mimic, of bacterial tRNA 127
- Docking methods 368
 genetic methods 518–519
- DOCK program 518
- Domino reaction 309
- Dopamine D₁ receptors 127
- Dopamine D₃ receptors 173
 antagonists 82, 261, 399
 partial agonists 82
- Dopamine D₄ receptors, antagonists 353, 399, 448
- Dopamine receptors, antagonists 399
- D-optimal designs 280
- Drug conformation 185–188
- Drug delivery systems
 antisense
 oligodeoxynucleotides (ODNs) 425–426
 oligosaccharide application 527
 strategic use 406–407
 testing and development 407
- Drug design
 computer-aided 71, 231–238
 evolutionary and genetic methods 514–521
 genomics impact 474–480
 nucleotide sequences leading to 477
 strategy 72
see also Rational drug design
- Drug development
 antisense vs traditional 417
 efficiency improvement proposal 209–216
 history 209–210
 virtual corporations 255–260
- Drug discovery, principles 530–531
- Drug Discovery for the Modulation of Signal Transduction and Gene Transcription* (CR) 50–52
- Drug Discovery Today*, editorial outline 1
- Drug metabolism, *see* Metabolism
- (+)-Duocarmycin A 219
- E**
- ECE (endothelin converting enzyme) inhibitors 399
- Egr-1 transcription factor 309
- Eicosanoids, release triggered by aspirin 49–50
- Elitism, in evolutionary algorithms 515
- Emerging drugs (BR) 460
- 'Emerging pathogens' 227
- Enalapril, in depression 537
- Enalaprilat 186
- Enantiocontrolled synthesis 491
- Enantiomers 145–150
- Enantioselective catalysis 145–150
- Encoding strategy, novel 537
- Endosomal acidification 320
- Endothelin converting enzyme (ECE) inhibitors 399
- Endothelin receptors (ET)
 antagonists
 3D pharmacophoric diversity 78
 ET_A/ET_B 62–63, 65–68
 ET_A-selective 61, 62, 64, 399
 ET_B 68
 nonpeptide 60–70
 subtypes ET_A and ET_B 60–61
- Englitazone 110, 111
- Enkephalins 165
- Entactin 302–303
- Enzyme(s)
 drug metabolizing (liver) 214–215
 glycosylation 340–341
 intracellular, in neurodegeneration treatment 457–458
 in metabolic screens 210–211
 oligosaccharide synthesis 527
 protein kinase inhibitors 325–330
- Enzyme assays 291–293
- Enzyme-based glycosylation technology 31, 33
- Enzymic phosphorylation, indirect 124
- Epalrestat 221
- EPDOCK program 518
- Epidermal growth factor receptor (EGFR) 325–327, 448
- Epilepsy 107, 379
- Epivir 413
- Epoetin alfa, award to discoverer 4
- ErbB-2 325
- erbB* gene 325–327
- L-(+)-Ergothioneine 84
- Erythema, UV-induced 347
- Erythropoietin, recombinant, award to development team 4
- E-selectin, ligands 490
- EST (expressed sequence tags) 12–13, 475–476
- Estrogen
 biosynthesis 308
 inhibition 308, 449
 steroid sulfatase inhibitors 308
 receptor modulators, selective 217
 tissue-specific therapy 538

- Etoposide 346, 348–349
 Eureka award 387
 European Agency for the Evaluation of Medicinal Products (EMA), Gonal-F® approval 2
 European Molecular Biology Laboratory (EMBL) 272
 Evolutionary algorithms 514
 Evolutionary programming 514
 Excitatory amino acids 456
 Experimental design
 277–286
 analysis and interpretation 281–282
 antisense oligonucleotides 417–418
 classical 278–280
 D-optimal designs 280
 fractional factorial 279–280
 full factorial 279
 response surface modeling 280
 radioligand binding assay 284–286
 scintillation proximity assays 282–284
 space-filling 282
Exploiting Molecular Diversity (CR) 132–133
 Expressed sequence tags (ESTs) 12–13, 475–476
 Ezrin 451
- F**
 Famciclovir (Famvir®) 90
 Familial adenomatous polyposis (FAP) 495
 FANA 393, 394–395
 Feeding behaviour 380
 Fibrinogen 299–300
 receptor antagonist 399
 Fibronectin 300
 First European Congress of Chemotherapy 315
 Fitness function 514
 FK453 533
 FK506 (tacrolimus) 187, 188
 FK506-binding protein (FKBP12) 406
 FKBP-rapamycin-associated protein (FAP) 406
 Flavin-containing monooxygenases 212
 Fluorescence acceptor 314
 Fluorescence assays, homogenous time-resolved 313
 Fluorescence probes 314
 Fluorophores 496
 Fluorous solvents 450
 Fluoxetine, chemoenzymatic synthesis of (R)-enantiomer 449
 Fluticasone propionate 200
 Flutimide 390
 Follicle stimulating hormone, recombinant (r-hFSH), Gonal-F® 2
- Food and Drug Administration (FDA)
 antisense oligonucleotide evaluation 427
 drug approvals 413, 473
 Merrem 387
 speeding up 45
 Fosarnet 390
Fourth Annual Development of Small Molecular Mimetic Drugs (CR) 408–410
 FR 900848 219
 Fractional factorial design 279
 Fungal infections 227–228
 Fungal phospholipase D inhibitors 262
 Furan, nucleoside synthesis 307
 Futhan 323
- G**
 GABA 106
 GABA_B receptors 371–380
 agonists and antagonists 374, 377
 characterization and subtypes 371–373
 distribution in CNS 373–374
 structure–action studies 374–376
 therapeutic applications 376–379
 Galanthamine 55, 58
 Galardin™ (Glycomed) 24, 25
 Gamma-aminobutyric acid, *see* GABA
 Gastrin receptor inhibitors 353
 Gastrointestinal absorption 181–185, 462–463, 466–468
 Gelatinase, inhibitors 21, 23
 GEM 91 420
 Gene(s), 5'-regulatory sequences 92
 Gene delivery 407
 Gene expression, transcription factors in 151–153
 'Gene knock-in' 92
 Gene therapy
 antisense 415–428
 delivery 407
 ribozyme application 101
 Genetic algorithms (GAs) 309, 514–521
 Genetic methods, in drug design 514–521
 Gene transcription, *see* Transcription; Transcriptional factors
 Genistein 327
 Genome 91
 automated analysis 273–274
 sequence information impact on drug discovery 126
 Genome sequencing 92, 126, 177–178
 GlaxoWellcome–SmithKline Beecham agreement 387
 licence from Human Genome Sciences 501
 Genome Therapeutics 91
- Genomics 177–178, 311
 impact on drug design 474–480
 intellectual property rights and 454
 GERM method 518
 GG 167 359–360, 393, 394–395
 inhibitors derived from 395–396
 resistance 359
 Gilead Sciences, Vistide marketing in US 413
 GlaxoWellcome
 Epivir approval 413
 genomic sequencing collaboration agreement 387
 research projects and plans 48
 support for Cruciform Project 88
 GLUT 4 transporter 111
 Glutamate receptors 504
 metabotropic, *see* Metabotropic glutamate receptor (mGluR)
 Glycal-based donor technology 31
 Glycines, N-substituted, small-molecule library 134–136
 Glycoconjugates 331, 522
 generation of libraries 27–34
 solid-phase synthesis 29–33
 Glycopeptides
 solid-phase synthesis 30–33
 vaccines based on 190–198
 Glycoprotein receptors 509
 Glycosidic bond synthesis 333
 Glycosylation 30, 333
 anomeric control 334–335
 chemoselective 336–339
 enzymatic and semisynthetic strategies 340–341
 one-pot multistep 336–339
 Glycosylsulfoxide donor technology 30
 Go 6976 327
 Gonal-F®, EMA approval 2
 GP80 303
 G-protein-coupled receptors
 103, 499, 502–513
 activation 510
 agonists and antagonists 505–510
 antibodies to 512
 binding-site locations 508–510
 book review 9
 calcitonin subfamily 504, 507, 510
 genomics application 479
 glutamate-metabotropic subfamily 504
 see also Metabotropic glutamate receptor (mGluR)
 inverse agonists 505–510
 rhodopsin subfamily 504, 506–507, 508–509
 structural characterization/features 502–504
 study methods 510–512

- subfamilies 504–505
- Granuloma 347
- Green fluorescent protein 496–497
- 'Grow' method 518
- Growth factors 325–327, 448
- 4-Guanidine-Neu5Ac2en 331, 332
- Gulliver effect 361
- H**
- H₃ receptor antagonists 306, 534
- H-7 (protein kinase inhibitor) 327
- Hairpin ribozyme motif 94
- Halenquinol 491
- Halenquinone 491
- Hammerhead computer program 410
- Hammerhead ribozyme motif 94
- Hansch analysis (BR) 362
- H-bonding capacity 464
- Health economics 117, 119
- Helicobacter pylori*, adhesion inhibitors 524
- Heliosynthese, EEC Eureka award 387
- Hemagglutinin 318–320, 322–323
- Heparin derivatives 332, 333
- Heparinoids 527
- Hepatic first-pass 468–471
- Hepatitis B, chronic 513
- Hepatitis B virus (HBV) inhibitors 353
- Hepatocytes, human liver 214
- Heptyl-physostigmine 55
- Heterocycles 133
- High-density assay plates 313
- High-fluidity supports 536
- High-throughput screening (HTS) 85, 91, 93, 230, 311, 458
 - compound databases 363
 - data management 273
 - experimental design 277–286
 - see also* Experimental design
 - genomics impact 478, 480
 - ISLAR '95* symposium (CR) 7, 8
 - ligands for G-protein-coupled receptors 511
 - natural products 270–271
 - ultra-high 267–268, 313–314
 - see also* Database;
 - Scintillation proximity assay
- (+)-Himbacine 41
- Histamine H₃ receptor antagonists 306, 534
- HIV-1
 - inhibitor 170, 353
 - integrase inhibitor 170
 - Nef protein 264, 450–451
 - reverse transcriptase inhibitors 122
- HIV infection
 - drug treatment 52
 - inhibitors 353
 - ribozyme application 99–100
- HIV-Nef binding 450–451
- HIV protease inhibitors 138–139, 533–534
 - azacyclic acid-based 261
 - developmental status of lead compounds 185
 - from aminimide library 253
 - novel 253, 261, 533–534
 - pharmacokinetic parameters 183
 - transition-state analog 138–139, 140
- Horizontal integration, in pharmaceutical industry 117, 118
- House of Lords, Biogen v. Medeva patent dispute 35–38
- Houseman, D.E., award 397
- H-ras gene, ribozyme action 100
- 5-HT_{1D} receptor agonists, non-indole 123
- 5-HT₃ receptor ligands 448
- 5-HT₄ receptor antagonists 305–306
 - selective 83
- Human adenovirus protease 309
- Human Genome Project 12, 126, 454
- Human Genome Sciences (HGS) 85, 474–475
 - licence for genome sequence use 501
- Humphrey, P., award 90
- Huperzine A 55
- Hydantoins 141
- Hydrophobic drugs, oral absorption, award for research 4
- Hydroxamic acid 17, 20
- 4-Hydroxyandrost-4-ene-3, 17-dione 449
- 2-Hydroxybaclofen 374
- 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors 169–170
- 2-Hydroxysaclofen 371, 372
- Hydroxystilbene 141
- Hydroxytryptamine receptors, *see entries beginning* 5-HT
- Hyperacute rejection, prevention by oligosaccharides 525–526
- Hyperglycaemia 109
- Hypocholesterolemic agents, antioxidant 261
- Hypoglycaemic agents 226
- I**
- ICAM-1 298–299
- ICAM-2, recognition by natural killer cells 451
- ICI 204219 (Zafirlukast) 201
- α -L-Iduronidase inhibitors 306
- Ifenprodil 457
- I- κ B 85
- Imidazole derivatives 307
- Imidazole thiazoles 64
- Imidazoline 1 receptor-specific agent 306
- Immune disease, NF-AT and 156
- Immunization, passive and active 386
- Immunogenicity, polysaccharide–protein conjugates 384
- Immunoglobulin E (IgE) modulators 206
- Immunoglobulin G (IgG) superfamily 298–299
- Immunoglobulin M (IgM), piezoelectric immunosensor 223
- Immunosensors, piezoelectric 223
- Immunosuppressants, pharmacokinetic parameters 183
- Immunotherapy
 - active specific (ASI) 196
 - cancer 190–198
- Incyte Pharmaceuticals, collaborative agreement 521
- Indane carboxylic acids 67
- Indazole 489
- Indolocarbazoles 439–440
- Infectious disease, transcription factors and 157
- Inflammation, agents preventing 205–207
- Inflammatory disease, NF- κ B and 157–158
- Influenza virus 316–324
 - adsorption 318
 - antiviral agents 359–361
 - fusion with host cell membranes 322–323
 - inhibition of 388–397
 - DNA/RNA polymerases 389
 - endonuclease 390
 - packaging and release 392–394
 - viral fusion 323
 - viral uncoating 320–322
 - life cycle 319
 - packaging 392
 - release 392–394
 - replication 388–392
 - uncoating 320–322
 - vaccination 317
- Influenza virus inhibitors 316–324, 359–361
 - t*-butyl hydroquinone action 360
 - hemagglutinin binding 318–320
 - influenza matrix protein 360
 - neuraminidase 359–360
 - podocarpic acid compound 360
 - see also* Influenza virus, inhibition of
- Innovation strategies 403
- Insecticides, novel 270–271
- Institute for Strategic Medical Research 88
- Insufficiency, biotechnology patents 37–38

- Insulin resistance 109–116
 β_3 -adrenoceptor agonist action 113–116
thiazolidinedione action 110–113
Integrins 297–298, 493
Intellectual property rights 453–454
Interferon, licensing 387
Interferon- α (IFN- α) 493
Interleukin-1 β converting enzyme (ICE) 448
Interleukin-12 493
International Protein Data Bank (PDB) 315
International Symposium on Laboratory Automation and Robotics (ISLAR '95) (CR) 7–9
International Symposium on Medicinal Chemistry – XIVth (CR) 498–500
Internet 130, 272–273
3D database searching 237
Intestinal absorption 181–185, 462–463, 466–468
Intestinal peptidases 465
Intracellular enzymes 457–458
Intranets 273
Introns 94
Invasive strategies, peptide delivery 162–163
In-vitro and *in-vivo* correlations 175, 215–216
Ion channel blockers, M2 321
Iontophoresis, reverse 407
ISIS 2105 420
ISIS 2922 420
ISIS 3521 420
Isis Pharmaceuticals, patent for C-raf kinase 521
ISLAR '95 'More for less' (CR) 7–9
Isolated perfused rat liver (IPRL) studies 469–470
Isoproterenol 498, 499
Isotopic encoding, bead libraries 538
Isoxazolones 445
Isozymes, protein kinase C 438
- K**
Kainate receptor antagonists 456
Ketals, cleavage 219
Kidney stone diseases 223
Kinase inhibitors, *see* Protein kinase inhibitors
Kinetic resolution 263
Kinetics, medicinal chemistry challenge 531
Kininogen 302
Knoevenagel–ene process 309
- L**
L 733560 498
L 734217 172
L 735882 389, 390
L 744832 498
L 754142 203
- β -Lactamase reporter system, fluorescent probes 314
 β -Lactam antibiotics 141
pharmacokinetic parameters 182
Lactones, reduction 124
Lactulose 331, 332
Laminin 301–302
Lead compounds
automatic generation 46
de novo design 519–520, 520
generation, *see* Lead generation
Lead discovery, evolutionary and genetic algorithms 517–520
Lead generation 11–15, 71–78
automatic 46
biological target discovery 11–15
combinatorial library technology 27–34
genomics impact 478
molecular diversity evaluation 71–78
natural products 270
small-molecule combinatorial chemistry 134, 143
solution-phase synthesis 248–254
see also Combinatorial chemistry; Combinatorial library
Lead optimization 253–254, 274, 520, 530
Lead structures, identification using solid-phase synthesis 42–43
Leiden/Amsterdam Center for Drug Research (LACDR) 404
Leptin receptors 173, 477–478
Letrozole, approval in France 413
Leukaemia, antisense oligonucleotide therapy 420
Leukocyte-endothelial interactions 402
Leukotriene(s)
antagonists, in asthma 200–201
biosynthesis inhibitors 200–201
Leukotriene B₄ receptor antagonists 123, 534
LG 50643 369
Library design optimization 266, 309
Library generation
strategies 132
video reviews 275
see also Combinatorial library; Compound libraries; Small-molecule libraries
Lin, F.-K., award 4, 5
Liners 222
Lipids, cationic, *see* Cationic lipids
Lipophilicity 463–464
Lipoprotein-associated phospholipase (Lp-PLA₂) 477
- Liposomes 97, 194
antifungal preparations 228
antisense oligodeoxynucleotides (ODNs) delivery 426
International Symposium on Medicinal Chemistry 500
vaccines based on 190–198
5-Lipoxygenase activating protein (FLAP) inhibitors 201
5-Lipoxygenase inhibitors 200–201
15-Lipoxygenase inhibitor 170
Lisinopril 186
Liver
cytochrome P-450 211–212
drug metabolizing enzymes 214–215
microsomes, human 211
Phase II enzyme studies 213–214
slices 214
Losartan 39, 536
Low density lipoprotein (LDL), receptor, upregulator 77–78
Lp-PLA₂ 477
L-selectin protease 402
Lung tumors 197
LY 180299 360
LY 214624 390, 391
LY 231617 457, 458
LY 253963 390, 391, 392
LY 264826B (chloreremomycin) 361
LY 293111 201
LY 297336 390, 391
LY 307987 390
LY 341495, (S,S,S)- 498
Lymphoma, antisense oligonucleotide therapy 420
- M**
M2 ion channel blockers 320–322
M2 protein 320
M₃ agonists 305
Macrosearch on NMR data 435–437
Magic angle spinning (MAS) NMR 459
Malaria 350
Male contraception/
contraceptives
proton-pumping ATPase and 309
target for 126–127
MAP4 (α -methyl-2-amino-4-phosphonobutyric acid) 105
MAPK/ERK kinase 328–329
Marine micro-organisms
biosynthetic pathway transfer to commercial microbes 48–49
drug discovery by Pfizer 4
Mast cell tryptase inhibitors 206
Matrix metalloproteinase (MMP)
16
inhibitor complexes 16
membrane-type (MT-MMP) 17

- structure 20
- Matrix metalloproteinase (MMP)
 - inhibitors 16–26
 - clinical trials 24–25
 - natural products 24
 - orally active 24
 - pseudopeptide inhibitor design 17–24
 - structure–activity relationship 17–24
- MCCG-1 (α -methyl-carboxycyclopropylglycine) 105, 498
- trans*-MCG-1 105
- Medeva, hepatitis B virus antigen patent dispute 35–38
- Medicinal chemistry
 - antisense
 - oligodeoxynucleotides (ODNs) 424–425
 - book review 412
 - challenges 529–532
 - symposium 498–500
- MEK (MAPK/ERK kinase) 328–329
- Melatonin 498
 - receptor ligands 498
- Melittin 436
- Mercaptoacylprolines, solid-phase synthesis and library 138
- Merrem, FDA approval 387
- Metabolism
 - medicinal chemistry challenge 531
 - strategies for drug development 209–216
 - cytochrome P-450 211–212
 - flavin-containing monooxygenases 212–213
 - hepatocyte and liver slice studies 214
 - in vitro*–*in vivo* correlations 215–216
 - metabolic enzyme screens 210–211
 - Phase II enzyme studies 213–214
 - pure drug metabolizing enzymes 214–215
- Metabotropic glutamate receptor (mGluR) 103, 456–457, 504
 - agonists 103–106
 - antagonists 103–106, 262, 498
 - ligands, subtype-selective 456–457
 - synaptic integration/transmission and plasticity 106
 - therapeutic potential of drugs 106–108
- Metalloelastase (MMP 12) 17
- Methoxypropene 147
- Methyl acetate 147
- N*-Methyl-D-aspartate, *see* NMDA
- 1-Methylgalanthamine 56
- 1-Methylphysostigmine 57
- Metrifonate 55
- Michael addition 84
- Microautoradiographic screening 402
- Micro-miniaturized sensor systems 268
- Microplate technology, 96-well 267
- Micro-sequencing techniques 27
- Microtubule inhibition, by podophyllotoxin 345–346
- Miniaturized screening systems 267
- Mitochondrial DNA 513
- Mitogen, stimulation 347
- Mitogen-activated protein kinase (MAPK) 328–329
- Mitokor, gene defect in Parkinson's disease 513
- MK 476 (Montelukast) 201
- MK 591 201
- Molecular biology, computer modelling (BR) 500
- Molecular diversity 129, 132–133
 - evaluation 71–78
- Molecular framework analysis 537
- Molecular packaging 167–168
- Molecular pharmacology 103–108
- Molecular targets, emerging 42, 85, 126–127, 173, 223, 264, 309, 355, 402, 450–451, 494, 538
- Molecular weight 181, 463
- Monoamine(s), receptors 506, 508
- Monoamine oxidase (MAO) inhibitor 305
- Monoindolylmaleimides 442
- Monooxygenases, flavin-containing in liver 212
- Montelukast (MK 476) 201
- Motor control 378
- mRNA, *rex/tax*, ribozyme cleavage 101
- MUC-1 mucin 190–198, 526
- Multiple drug resistance (MDR)
 - protein kinase C link 492
 - taxol derivatives 497
- Münchnones 308
- Muscarinic agonists 305
 - in Alzheimer's dementia 55
- Muscarinic antagonists 203–204
 - 3D-database searching 367
- Mutagenesis, site-directed 496–497
- Mutations
 - β_3 -adrenoceptors in diabetes/obesity 114
 - point, G-protein-coupled receptors 511–512
 - presenilin genes in Alzheimer's disease 453
- Myelin, synthesis, regulation by progesterone 5
- Myocardial infarction 269
- N**
- Naphthol[1,2-*b*]pyrans 221
- Napp Research Centre 87
- National Institutes of Health (NIH), patent profile 92
- Natural killer (NK) cells 451
- Natural products
 - high-throughput screening 270–271
 - matrix metalloproteinase inhibitors 24
 - Pfizer's research agreements 4
 - protein kinase C inhibitors 445–446
 - synthesis (BR) 412–413
- Natural selection 514
- NBOX 457
- nef* gene 451
- Neoplasia, *see* Cancer
- Nerve growth factor (NGF) 164
- Neuraminidase 318, 319
 - inhibitors 359–361, 392–394
- Neurodegeneration 176–177
 - acute, treatment advances 456–458
 - chronic disease 107
- Neurokinin NK₁ receptor
 - antagonists, *see* NK₁ antagonists
- Neuronal scaffold protein 264
- Neuropeptides, genomics application 479
- Neuropsychiatric disease 107–108
- Neutrophil chemotaxis, inhibition by podophyllotoxin 346
- New chemical entities (NCE) 461
- New Drug Approval (NDA)
 - Gonal-F® 2
 - review time reduced 45
- NF-AT and immune diseases 156
- NF- κ B 85, 153, 157–158, 357
 - induction of nitric oxide synthase 450–451
 - inhibitor 358
- Nicotinic agonists 55
 - in Alzheimer's dementia 54–55
 - noncompetitive agonists (NCAs) 58–59
- Nicotinic ligands 53, 55
- Nicotinic receptors 53, 55
 - allosteric modulation 55–57
- NIDDM (non-insulin-dependent diabetes mellitus) 109–116
- Nitrendipine 221
- Nitric oxide
 - inhibitors 202–203
 - sensors 172
- Nitric oxide synthase (NOS) 457
 - inducible (iNOS) 450–451
 - inhibitors 202–203, 352
 - neuronal isoform (nNOS) 457
- NK₁ receptor antagonists 169, 265, 490
 - 3D-database searching 366–367
- NK₃ receptor antagonists 398–399, 498

- NMDA 456
 receptor subtypes 456
 NMR
 macrosearch data 435–437
 magic angle spinning 459
 Non-steroidal antiinflammatory drugs (NSAIDs) 495–496
 N-Norcodeine 58
 Novartis 176, 228
 integration process (phase 1) 387
 Novel leads, computer-based screening of database 363–370
 NS 420 457
 NSAIDs 495–496
 Nucleosides, synthesis from furan 307
 Nyotran 228
- O**
 Obesity 113
 novel drugs 226
 ob gene 477–478
 Obviousness, biotechnology patents 36–37
 Occlusive lesions, vascular 309
 Octahydroacridines 400
 Oestrogen, *see* Estrogen
 Oestrone sulfatase inhibitors 308
 Oligonucleotides
 antisense, *see* Antisense
 oligodeoxynucleotides (ODNs) in antisense research (BR) 230
 delivery 97
 Oligosaccharides 522–528
 adhesion inhibitors 522–526
 analogues 331–332
 applications 526–527
 biosynthesis modulation 526
 complex, preparation 333–341
 generation of libraries 27–34
 manufacture 527
 solid-phase synthesis 28–29, 339–340
 synthetic 331–341
see also Glycosylation
 Oncogenes 325–327
 inhibition by ribozymes 100
 ONO 1078 (Pranlukast) 201
 Optimization
 genetic algorithms in lead discovery 519
see also Lead optimization
Options for the Control of Influenza III (CR) 359–361
 Oral activity, matrix metalloproteinase inhibitors (MMPs) 24
 Oral bioavailability 179–189, 408–409
 carrier-mediated transport 181–185
 design principles 179–189
 conformational structure 185–188
 molecular flexibility 185–188
 molecular weight 181
 partition coefficient 180–181
 estimation and parameters in 179–180
 physicochemical and drug delivery aspects 461–473
 Organic chemistry of drug synthesis (BR) 229
 Organic nitrate esters 398
 Osteoclasts, apoptosis 538
 OX26 164
 Oxazoles 64
 Oxazolidinones 499
 Oxford Asymmetry 274
 Oxford BioMedica, flotation on stock market 473
 Oxford Diversity 274
 Oxindole 91
 Oxytocin antagonist 122
- P**
 Packard Instrument Company 313–314
 PAF (platelet-activating factor) 125, 205
 Pain 107
 Parallel synthesis 139
 Parkinson's disease 513
 Partition coefficient 180–181
 Partnering 79–81
 Partnerships, establishment in 1995 81
 Patents
 antisense oligonucleotides 427
 biotechnology, Biogen v. Medeva 35–38
 NIH 92
 obviousness and insufficiency 36–38
 Pathogens, 'emerging' 227
 PCR, *see* Polymerase chain reaction (PCR)
 PD 98059 327
 PD 156707 203
 PD 153035 327
 Penochalasin 217
 Peptide(s)
 binding to rhodopsin-like receptors 506, 508–509
 blood-brain barrier and 161–162
 chimeric 163–164
 delivery into CNS 161–168
 chemical delivery systems 165–168
 invasive strategies 162–163
 physiologically-based 163–165
 design of drugs 52
 design/synthesis of small-molecule combinatorial library 134–136
 esterase-sensitive prodrugs 500
 prodrugs 165
 Peptide fragments, synthesis 511
 Peptide library 450
 encoded 537
 Peptide Therapeutics 52
 Peptidomimetics 467
 design 408–410
 inhibitors 448
 Peptidylphosphonic acids 136–137
 Perfusion, oral bioavailability of renin inhibitors 462–463, 466–468
 Per genes 85
 Peripheral nervous tissues, GABA_B receptors in 380–381
 Permeability, oral bioavailability of renin inhibitors 462–463, 466–468
 Peroxisome proliferator-activated receptor G (PPARG) 112
 Pertussis toxin 303
 Pfizer
 drug discovery from natural products 4
 new products for approval and future plans 48
 Oxford Asymmetry agreement 274
 Phaclofen 371
 Pharmaceutical companies, on Internet 130
 Pharmaceutical industry
 collaboration over antisense oligonucleotides 427
 university collaboration 403–404, 404–405
 Pharmacia & Upjohn
 FDA approval for Camptosar 413
 licence for genome sequence use 501
 Vistide marketing 413
 Pharmacodynamics, antisense oligodeoxynucleotides (ODNs) 423
 Pharmacokinetics 408–409
 drug metabolism 215–216
 podophyllotoxin derivatives 348–349
 Pharmacophore
 diversity 74
 elucidation 515–517
 searching (3D) 366
 profiling methods 74–77
 protein-derived queries 367–368
 Pharmacophore-Derived Queries (PDQ) Method 74–77
 Pharmagene Laboratories, launch 473
 Phase II enzyme studies, liver 213–214
 Phenylacetamides 67–68
 Phenylalanine tRNA 127
 Phenyl derivatives, ET_A-selective antagonists 64
 4-substituted 2-Phenylloxazole-5-carboxylates 125
 Phenyl sulphonamide 65
 Phe-Pro-Arg-chloromethylketone (PPACK) 533

- Phosphodiesterase type-IV (PDE-IV), inhibitors 205
- Phospholipase A₂ inhibitors 534
- Phospholipase D inhibitors, fungal 262
- Phosphonate amides 125
- Phosphonate esters 125
- Phosphonobutoxypurine antivirals 533
- Phosphorothioate oligodeoxynucleotide 418, 419
- Phosphorylation indirect enzymic 124 transcription factor regulation 154–155
- Phosphotyrosine isosteres 263
- Photocrosslinking 512
- Physostigmine 55, 58
- Phytochemistry Diversity: A Source of New Industrial Products* (CR) 270–271
- Piclamilast (RP 73401) 203
- Picropodophyllin 345
- Piezoelectric IgM immunosensor 223
- Pioglitazone 110, 111
- Piperidine alkaloid, (+)-himbacine 41
- PLA₂ (phospholipase A₂) inhibitors 534
- Plasmodium falciparum* 303
- Plasticity, synaptic 106
- Platelet-activating factor (PAF) 125, 205
- Platelet factor 4 (PF4) 493
- Plates 96-well 9 high-density assay 313
- PMP [N-(3-pyridylmethyl)pyrrolidine] 55
- Pneumocandins 499
- Podophyllotoxin 343, 344–345
- Podophyllotoxin derivatives 343–351 anti-inflammatory activity 346–348 drug development and applications 350–351 pharmacokinetics 348–349 pharmacological activity 345–346
- Poggiolini, D., book publication 4–5
- Polycarbamates, small-molecule combinatorial library 134–136
- Polyene, lipid formulations 228
- Polymerase chain reaction (PCR) 13–15 quantification 293
- Polymeric supports 459–460
- Polysaccharides, capsular, *see* Capsular polysaccharides
- Potassium channel openers (KCOs) 204
- Pouton, C., award 4
- Powderject™ technology 407
- Pranlukast (ONO 1078) 201
- Pravastatin 269
- Presenilin genes 453
- ProAmatine™, FDA approval 473
- Prodrugs activation 239–241 *International Symposium on Medicinal Chemistry* 500 peptide 165
- Progesterone, myelin synthesis regulation 5
- Proliferative diseases 404
- Prolifix 404–405
- Propanoic acids 67
- Propenoic acids 67
- Prostaglandin D₂ (PGD₂) agonists 262
- Protease digestion studies 503
- Protease inhibitors, HIV, *see* HIV protease inhibitors
- Proteasomes 450–451
- Protein capsular polysaccharide conjugate vaccines 381–387 carrier, in conjugate vaccines 383–384 delivery 407 engineering 243–244
- Protein Data Bank (PDB) 315
- Protein-derived pharmacophore queries 367–368
- Protein farnesyl transferase inhibitors 410
- Protein kinase, inhibitors 448 cancer treatment 325–330 c-raf-1/MEK 328–329 EGFR/*erbB* 325–327 kinase targets 329 PKC, *see* Protein kinase C (PKC)
- Protein kinase A (PKA), α subunit 494
- Protein kinase C (PKC) 327 cancer link 327–328, 492 inhibitors 40, 327–328, 438–447 balanoids 442–444 isoxazolones 445 natural products 445–446 sphingolipids 444–445 staurosporine-related 439–442 multiple drug resistance (MDR) link 492
- Proton-pumping ATPase 309
- Pseudopeptide inhibitors, design and structure–activity 17–24
- Pseudopterosins 449
- Psoriasis 350
- Psychiatric disorders angiotensin II role 536–537 GABA_B receptors in 380
- Pyrazole libraries 252
- Pyrazolo[3,4-*b*]pyridines 400
- Pyridine derivatives 263
- Pyrroles, substituted 308
- Pyrrolidine carboxylic acids 64
- Pyrrolidines, solid-phase synthesis and library 138
- Pyrrolidinoisoquinoline derivatives, asymmetric synthesis 125
- Pyrrolo[2,1-*c*][1,4]benzodiazepine antibiotics 219
- Pyrrolo[2,3-*d*]pyrimidines 83–84
- Q**
- QSAR book review 362 chemometric methods (BR) 412 evolutionary algorithms 516 techniques 311–312
- Quantitative structure–activity relationship, *see* QSAR
- Quinazolines 458
- R**
- R&D future prospects 117–121 management 79–81 productivity, current crisis 45 successful strategies (BR) 501
- Radioimmunoassays (RIAs) 288–289
- Radioligand binding assay 284–288
- Raloxifene 538
- Rapamycin 406
- Ras farnesyltransferase 499
- 'Rational animal design' 92
- Rational drug design 531–532 genomics application 478–480 *see also* Drug design
- Rational screening set generation 72–73
- Rauwolfia alkaloids 450
- Reaction optimization 222
- Receptors binding assays 289–290 G protein-coupled (BR) 9 growth factor 325–327 synthetic 266 *see also* G-protein-coupled receptors; *other specific receptors*
- Regulatory approval 45 *see also* Food and Drug Administration (FDA)
- Regulatory issues, antisense oligonucleotides 427
- Renin inhibitors 185 analogs 463–473 oral bioavailability and drug delivery aspects 462–473
- ReoPro 303
- Reproduction studies, podophyllotoxin derivatives 348, 349
- Research collaboration 79–81, 88 University–industry 403–404, 404–405
- Research and development, *see* R&D
- Research strategies, drug R&D (BR) 501
- Resin capture methodologies 494
- Respiratory drug delivery 407

- Respiratory functions, GABA_B receptors in 380
- Response surface modeling 280
- Retinal neovascularization 355
- Retrosynthetic analysis (BR) 412–413
- Reverse transcriptase, inhibitors 122
- Reverse transcription 15
- rex/tax* mRNA, ribozyme cleavage 101
- RG 13022 327
- RGD sequence 295, 299–300
- Rheumatoid arthritis 350
- Rhinovirus 519
- Rhodopsin 502–503
- Rhodopsin-like receptors 504, 506–507, 508–509
- Rhône-Poulenc Rorer, Campto marketing application 413
- Ribavirin 390
- Ribozymes 94–102
- biology 97–99
 - chemistry and stability 96–97
 - synthetic, delivery 97
 - therapeutic applications 99–101
 - types and design 94–95
- Rimantadine 321
- RNA
- mRNA, *rex/tax* 101
 - splicing 94–102
 - tRNA, bacterial 127
- RNA fingerprinting 13–15
- Ro 319790 24, 25
- Ro 320432 327
- Roberts Pharmaceutical Corporation 473
- Robotics
- automatic generation of lead compounds 46
 - ISLAR '95* symposium 7, 8
 - problem-solving 481–488
 - ultra-HTS 313
- Rolipram 203
- Roulette-wheel selection 515
- RP 73401 (Piclamilast) 203
- S**
- S 20098 498
- Saccharide–protein conjugation 384
- Sandoz, Ciba-Geigy merger 176
- (–)-Sandramycin 171
- Saquinavir 90
- Satiety agent 489
- SB 207499 203
- SB 213785 498
- SB 223414 498
- SCH 50911 374, 376
- SciClone Pharmaceuticals, thymosin α 1 513
- Scintillation proximity assay 287–294
- application in RIAs 288–289
 - binding assays 290–291
 - enzyme assays 291–293
 - optimization 282–284
 - principle 287–288
- quantification of PCR by 293
- receptor binding assays 289–290
- Scotia Pharmaceuticals, EEC Eureka award 387
- Screening
- biomolecular 93, 267–268
 - computer-based 363–370
 - genomics impact 478
 - high-throughput, *see* High-throughput screening (HTS)
 - ligands for G-protein-coupled receptors 510–511
 - microautoradiographic 402
 - miniaturized systems 267
 - problem-solving in automation 481–488
 - whole-cell 357–358
 - see also* High-throughput screening (HTS); Ultra high-throughput screening
- SCRIPTGEN, collaborative agreement 521
- Search strategies, for information retrieval 272–273
- Secondary amines 220
- Selectin 296
- E-selectin, ligands 490
 - inhibitors 169, 524–525
 - L-Selectin protease 402
- Selection methods, catalytic antibodies 244–245
- Semisynthetic enzymatic glycosylation 340–341
- Sequencing
- human cDNA 177–178
 - human genes 92
 - see also* Genome sequencing
- Sequus Pharmaceuticals, report on Caelyx/Doxil 413
- Serine protease inhibitors 305
- Serine/threonine protein kinases 328, 438, 492
- Seven transmembrane (7TM) receptors 502–513
- Sheep red blood cell test 346–347
- Sialyl Lewis X antigen 332
- mimetics 490
- Sialyl-Tn 190, 191, 192, 195
- Siclofen 374
- Sigma-Aldrich information 131
- Signal Pharmaceuticals 357
- Signal transduction 151, 357, 358, 438
- G-protein-coupled receptors 506–507, 510
 - metabotropic glutamate receptor (mGluR) classification 104
 - recent advances (CR) 50–52
- Silicon Graphics, SpaceCrunch project 473
- Similarity searching 364–365
- SKF 38393 234, 235
- Skin grafts 347
- SM 208913 457
- Small-molecule(s)
- solid-phase synthesis 42–43, 134, 139–142
 - therapeutic agents 404–405
- Small-molecule combinatorial chemistry 134–144
- Small-molecule libraries 134–144
- design and synthesis 134–139
 - solid-phase synthesis 42–43
- Small-molecule mimetics 408–410
- SmithKline Beecham, genomic sequencing agreement 387
- Society for Biomolecular Screening 93
- Software, *see* Computer software
- Solid-phase synthesis 129, 132–133
- glycoconjugates 27–34
 - high-fluidity supports 536
 - meeting report 132–133, 458–459
 - oligosaccharides 27–34, 339–340
 - quinazolines 458
 - small molecules 134, 139–142
 - library generation 42–43
 - technology at Oxford Diversity 274
- Solid Phase Synthesis* (CR) 132–133
- Solid tumors, *see* Tumor, solid
- Solution chemistry, combinatorial 308
- Solution-phase synthesis 248–254, 459
- equipment and automation 249
 - fluorous solvents for 450
 - library approach and format 248–249
 - pooled library generation 249–250
 - quality control and decoding 249
 - single compound libraries 252–253
 - lead optimization 253–254
- Somatostatin ligand, nonpeptide 218
- SPA, *see* Scintillation proximity assay
- SpaceCrunch project 473
- Space-filling experimental design 282
- Spasticity 378
- Sphingolipids 444–445
- Sphingosine 444–445
- Spinal cord injury 107
- Spiro-pyridazino[4,5c]pyridazinones 535
- SQ 29852 (ceranapril) 536–537
- Squalene synthase inhibitors 82, 261
- SR 27417 203
- SR 48968 203
- SR 140333 367
- Src family of kinases 451

- Src SH3-binding domains 479, 480
- Stability, gastrointestinal 464–466
- Staphylococcus aureus*, drug resistance 361
- Statistics, experimental design 277–286
- Staurosporine 327, 439
- Stereochemical modulation 83
- Stereocontrolled synthesis 535
- Steroid(s), in asthma 199–200
- Steroid receptors
ET_A-selective antagonists 61
transcriptional activation 50–52
- Steroid sulfatase inhibitors 308
- Strategic alliances 79–81, 257, 258–260
genomics companies 454, 474–475
- Strategies for Identification of Novel Targets for Drug Discovery* (CR) 91
- Strathclyde Institute for Drug Research (SIDR) 226
- Streptozotocin 331, 332
- Stromelysin 309
inhibitors 21, 23
- Stromelysin 3 (MMP 11) 17
- Structure–activity relationships
matrix metalloproteinase inhibitors 17–24
see also QSAR
- ST-T 1213 497
- Stubbe, J., award 397
- Substance P 265
- 4-Substituted 2-phenyloxazole-5-carboxylates 125
- Substructure searching 364
- α -Sulphinyl carbanions 84
- α -Sulphonyl carbanions 84
- Sumatriptan 90
- Superbugs 315, 361
- Synaptic transmission 106
- Syndrome X 110
- Synthesis of drugs, organic chemistry (BR) 229
- Synthetic oligosaccharides 331–341
- Synthetic peptides, design and development 52
- Synthetic receptors 266
- Systematic search
applications 432–437
concepts and limitations 429–430
strategies 429–437
constrained (active analog approach) 432–433
macrosearch 435–437
ringsearch (conformational analysis) 433–435
sampling 430–432
- T**
- Tachykinin antagonists 204–205, 352
- Tacrine 55
- Tacrolimus (FK506) 187, 188
- Tanimoto coefficient 365
- Targeted delivery, antisense oligodeoxynucleotides (ODNs) 426
- Targets
see Biological targets;
Molecular targets
synthetic vaccines 192–193
- Taxane anticancer drugs
book review 131
synthesis 400
- Taxol 270–271
derivatives 497
- Team, building and leadership, *ISLAR '95* symposium 8
- Teichoic acid 29
- Tenidap 91
- Teniposide 346, 348–349
- 1,2,3,4-Tetrahydro- β -carboline 450
- Tetrahydropyrroloquinoline 307
- Thalidomide 493
- Theophylline 199
- Therapeutic profile, diabetic complications 221
- Theratope® 526
- THERATOPE® STn-KLH vaccine 196–198
- 1,2,4-Thiadiazoles 220
- C2-Thiazoles 459
- Thiazolidinediones 110–113
- 4-Thiazolidinone library 266
- Thiazolidinones 141
- Thiazoline-2-imines 459
- Thionucleosides 123
- Thiophosphonate amides 125
- Thiophosphonate esters 125
- Third European Forum on Combinatorial Chemistry & Automation: Applications for Accelerated Drug Discovery* (CR) 458–460
- Thomsen–Friedenreich (TF) structures 190, 191, 192, 195
- Three-dimensional database, *see* Database
- Three-dimensional pharmacophoric diversity 74
see also Pharmacophore
- Thrombin
inhibitors 533
receptor 402, 509
- Thrombospondin 303
- Thrombospondin-1 (TSP) 409
- Thromboxane A₂ 170
- Thromboxane-modulating agents 170
- Thymidylate synthase inhibitors 91
- Thymosin α 1 513
- Tim and *Per* genes 85
- Tiotropium bromide 203
- Tirandamycin B 172
- Tissue inhibitors of metalloproteinases (TIMPs) 16
- Tissue-specific estrogen therapy 538
- Titanium complexes 146
- 7TM receptors 502–513
- TNF (tumour necrosis factor), matrix metalloproteinase action 17
- TNP 470 493
- Tolrestat 221
- Tomudex™ 91
- Topiramate 331, 332
- Topoisomerase II inhibitors 122
- Topotecan 270–271
- Tournament selection 515
- Toxins, microbial, antagonists 524
- Transcription
recent advances (CR) 50–52
regulation 357–358
- Transcriptional activators, modified 50
- Transcription factors 151–160, 357
activation and dimerization 155, 159
drug development strategies 159–160
Egr-1 309
I- κ B 85
NF- κ B, *see* NF- κ B
post-translational modification 159
regulation 153–156
role in gene expression 151–153
role in human disease 156–158
synthesis 159
types 153
- Transdermal delivery 407
- Transition-state analog (TSA) haptens 239
- Transition-state analog (TSA) libraries 136–137
- Transmucosal delivery 407
- TRAP screening approach 410
- Triangle Pharmaceuticals 52
- Tricyclic pyridazino [4,5c]pyridazinones 535
- Triols, novel optically pure 124
- Tripos, SpaceCrunch project 473
- tRNA, bacterial, DNA mimic 127
- Troglitazone 110, 111
- Tropoloisoquinolines 171
- Trypsin inhibitor 251
- Tularik 357
- Tumor, solid
antisense oligonucleotide therapy 420–421
c-raf kinase trial 521
see also Cancer
- Tumor-derived cachectic factor 264
- Tumor immunology, animal models 194–195
- Tumour necrosis factor α (TNF- α), matrix metalloproteinase action 17
- Turbohaler inhalation system 133
- Tyrosine kinase inhibitors 40, 448

U

U 100766 498, 499
Ugi reaction, extended 308
Ultra-high-throughput screening
267–268, 313–314, 497
UN Convention on Biological
Diversity 271
'Universal' biphenyl library 355
University College London,
Cruciform Project 88
University–industry collaboration
403–404, 404–405

V

Vaccines
cancer 190–196
animal models 194–195
delivery systems
193–194
glycopeptide/carbohydrate-
based 190–198
human trials 196–198
oligosaccharide application
526
synthetic target molecules
192–193
capsular
polysaccharide–protein, *see*
Capsular
polysaccharide–protein
conjugate vaccines
conjugate 383–385
delivery systems 193–194
genomics role 178
Valsartan 221
Vancomycin resistance 315, 361

VanX inhibitors 262
Vascular injury 309
Vasoactive intestinal peptide (VIP)
agonists 204
VDDCs, *see* Virtual drug
development corporations
(VDDCs)
Vector delivery, ribozymes 99
Venereal warts 350
Vertical integration, in
pharmaceutical industry 117,
118–119
Viral disease, ribozyme
application 99–100
Virtual drug development
corporations (VDDCs)
255–260
contract research
organizations' role 257–258
core competencies 258–260
Virtual libraries 369–370
Virtual pharmaceutical companies
275
Virtual research centre 87
Virus
adsorption 318
uncoating 320–322
see also HIV-1; Influenza virus
Vistide 413
Vitronectin 302
receptors 355
VM 26 (teniposide) 346,
348–349
von Willebrand factor 303
purification 355
VP 16 (etoposide) 346, 348–349

W

Warts, venereal 350
Weight loss, protein kinase A
(PKA) and 494
Wetterlin, K., award 133
Whole cell screening 357–358
World Wide Web 130,
272–273

X

Xenotransplantation, blockade of
antibodies in 525–526
X-ray crystallography, matrix
metalloproteinases (MMPs)
20

Y

Yakult Honsha, Campto
marketing application 413
Yamanouchi Pharmaceuticals,
Consensus Interferon
licensing 387
Yeast genome sequences
126
YM 934 203

Z

Zafirlukast (ICI 204219) 201
ZD 1694 91
ZD 9331 91
Zeneca, Merrem approved by
FDA 387
Zileuton 201
Zinc-binding group (ZBG), matrix
metalloproteinase inhibitor
design 17–21